|Bid||5.42 x 1800|
|Ask||5.68 x 3000|
|Day's range||5.42 - 5.85|
|52-week range||2.60 - 7.65|
|Beta (5Y monthly)||-0.68|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.81|
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.
Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
LAVAL, Quebec, November 10, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ending September 30, 2021.